DDInter1042 DDInter740
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
Flecainide {u} (Compound) causes {v} (Side Effect) Shock
Flecainide (Compound) resembles Mefloquine (Compound)
Flecainide (Compound) binds CYP2D6 (Gene)
Flecainide (Compound) upregulates MTHFD2 (Gene)
Flecainide (Compound) downregulates RRM2 (Gene)
Flecainide (Compound) causes Shock (Side Effect)